Asian Currencies Stay Rangebound as Yen Firms on Intervention Talk 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 
Asian Markets Surge as Japan Election, Fed Rate Cut Bets, and Tech Rally Lift Global Sentiment 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Lee Seung-heon Signals Caution on Rate Hikes, Supports Higher Property Taxes to Cool Korea’s Housing Market 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Gold and Silver Prices Climb in Asian Trade as Markets Eye Key U.S. Economic Data 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves 
Novartis unveiled its restructuring plans on Tuesday, June 28, but the program may also lead to job cuts, and around 8,000 employees are set to be affected. The Swiss -American multinational pharmaceutical company headquartered in Basel, Switzerland and Cambridge, Massachusetts, said that the reduction of its workforce will give them a savings of up to $1 billion by the year 2024.
As per Reuters, Novartis actually announced its restructuring program weeks before, and it has reaffirmed that it is set to let go of around 7.4% of its total workforce globally. The firm said that up to 1,400 workers based in Switzerland are also affected.
Previously, the projected job cuts were revealed by Novartis' chief executive officer, Vas Narasimhan. He explained back in April that it will be a "single digit thousands," and the company is doing this as part of a reorganization to save money.
The company shared through an email message that since the announcement, it has made good progress in the implementation of its new organizational structure. Under the program, Novartis has merged its pharmaceuticals and oncology business divisions. On the downside, this move entails the termination of some job roles throughout the organization.
"This restructuring could potentially impact 1,400 positions based in Switzerland, out of around 8,000 positions impacted globally," the company was quoted as saying in the email. The termination of workers was also confirmed by a local Swiss paper TagesAnzeiger. Currently, Novartis employs 108,000 staff worldwide, and 11,600 of them are based in Switzerland.
The restructuring comes as the company's chief Narasim is trying to bolster his efficiency credentials since Novartis is receiving huge cash windfalls that include a $20.7 billion last year from the sale of its 33% stake to its rival company, Roche.
Meanwhile, Bloomberg reported that the latest layoffs will fall heavily on the company's operations in Switzerland since it will be eliminating more than a thousand workers. The company also clarified that it has initiated consultations with employees at its HQ prior to the cutbacks.
"The new structure will be both leaner and simpler and as such the company intends to eliminate roles across the organization, subject to local information and consultation requirements," Novartis explained.
